S. Jurner

PAGE: 1

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/267,511

DATE: 02/10/2000

TIME: 12:11:55

Input Set: I267511.RAW

This Raw Listing contains the General Inferration Section and up to first 5 pages.

```
<110> APPLICANT: Brenneman, Douglas E.
 2
           Spong, Catherine Y.
 3
           Gozes, Illana
 4
           Bassan, Merav
 5
           Zamostiano, Rachel
 6
           The Government of the United States of America
 7
           as represented by the Secretary of the
           Department of Health and Human Services
 8
 9
           Ramot University Authority for Applied Research
           and Industrial Development, Ltd.
10
     <120> TITLE OF INVENTION: Prevention of Fetal Alcohol Syndrome and Neuronal Cell
11
           Death With ADNF Polypeptides
12
     <130> FILE REFERENCE: 015280-377000US
13
14
     <140> CURRENT APPLICATION NUMBER: US/09/267,511
     <141> CURRENT FILING DATE: 1999-03-12
15
     <160> NUMBER OF SEQ ID NOS: 26
     <170> SOFTWARE: PatentIn Ver. 2.1
17
18
     <210> SEQ ID NO 1
19
     <211> LENGTH: 9
20
     <212> TYPE: PRT
21
     <213> ORGANISM: Artificial Sequence
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence:activity
23
           dependent neurotrophic factor I (ADNF I) active
25
           site
26
     <400> SEQUENCE: 1
27
           Ser Ala Leu Leu Arg Ser Ile Pro Ala
28
             1
29
     <210> SEO ID NO 2
     <211> LENGTH: 8
30
31
     <212> TYPE: PRT
    <213> ORGANISM: Artificial Sequence
32
     <220> FEATURE:
33
     <223> OTHER INFORMATION: Description of Artificial Sequence:activity
           dependent neurotrophic factor III (ADNF III)
           active site
36
37
     <400> SEQUENCE: 2
           Asn Ala Pro Val Ser Ile Pro Gln
38
39
             1
40
     <210> SEQ ID NO 3
41
    <211> LENGTH: 89
     <212> TYPE: PRT
42
43
     <213> ORGANISM: Artificial Sequence
     <220> FEATURE:
44
```

PAGE: 2

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/267,511

DATE: 02/10/2000 TIME: 12:11:55

```
<223> OTHER INFORMATION: Description of Artificial Sequence: ADNF I
45
46
        polypeptide
47
    <220> FEATURE:
48
   <221> NAME/KEY: MOD_RES
   <222> LOCATION: (1)..(40)
49
    <223> OTHER INFORMATION: Xaa = any amino acid, Xaa at positions 1-40 may be
50
51
        present or absent
   <220> FEATURE:
52
53
   <221> NAME/KEY: MOD RES
   <222> LOCATION: (50)..(89)
54
   <223> OTHER INFORMATION: Xaa = any amino acid, Xaa at positions 50-89 may
55
        be present or absent
   <400> SEQUENCE: 3
57
58
        10
59
60
        25
61
                  20
        Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Ala Leu Leu Arg Ser Ile Pro
62
63
                              40
        55
65
        66
                                       75
67
                        70
68
        Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
69
                     85
70
   <210> SEQ ID NO 4
   <211> LENGTH: 88
71
72
   <212> TYPE: PRT
73
   <213> ORGANISM: Artificial Sequence
74
   <220> FEATURE:
   <223> OTHER INFORMATION: Description of Artificial Sequence: ADNF I
75
76
        polypeptide
77
   <220> FEATURE:
   <221> NAME/KEY: MOD RES
78
79
   <222> LOCATION: (1)..(40)
   <223> OTHER INFORMATION: Xaa = any amino acid, Xaa at positions 1-40 may be
80
        present or absent
81
   <220> FEATURE:
82
   <221> NAME/KEY: MOD RES
83
   <222> LOCATION: (49)..(88)
84
   <223> OTHER INFORMATION: Xaa = any amino acid, Xaa at positions 49-88 may
        be present or absent
86
   <400> SEQUENCE: 4
87
        88
89
                     5
                                    10
90
        91
                              / 25
                                                30
92
        Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Ala Pro Val Ser Ile Pro Gln
93
                              40
94
```

DATE: 02/10/2000 3 RAW SEQUENCE LISTING PAGE: TIME: 12:11:55

PATENT APPLICATION US/09/267,511

```
55
                                                       60
                50
 95
           75
                                                                       80
            65
                                70
 98
           Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 99
                            85
      <210> SEQ ID NO 5
100
101
      <211> LENGTH: 5
102
      <212> TYPE: PRT
103
      <213> ORGANISM: Artificial Sequence
104
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence:1-R or 2-R in
105
106
           ADNF I polypeptide formula
107
      <400> SEQUENCE: 5
108
           Val Leu Gly Gly Gly
109
             1
110
     <210> SEQ ID NO 6
     <211> LENGTH: 10
111
      <212> TYPE: PRT
112
113
     <213> ORGANISM: Artificial Sequence
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence:1-R in ADNF I
115
           polypeptide formula
116
     <400> SEQUENCE: 6
117
           Val Glu Glu Gly Ile Val Leu Gly Gly Gly
118
119
             1
                             5
                                               10
120
     <210> SEQ ID NO 7
121 <211> LENGTH: 5
122
     <212> TYPE: PRT
     <213> ORGANISM: Artificial Sequence
123
124
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence: 3-R or 4-R in
125
           ADNF III polypeptide formula
126
127
      <400> SEQUENCE: 7
128
           Leu Gly Leu Gly Gly
129
             1
130
     <210> SEQ ID NO 8
131
     <211> LENGTH: 7
132
    <212> TYPE: PRT
     <213> ORGANISM: Artificial Sequence
134
     <220> FEATURE:
135
     <223> OTHER INFORMATION: Description of Artificial Sequence: 3-R in ADNF
136
           III polypeptide formula
137
     <400> SEQUENCE: 8
           Ser Val Arg Gly Leu Gly Gly
138
139
             1
140
    <210> SEQ ID NO 9
141 <211> LENGTH: 4
142
     <212> TYPE: PRT
143 <213> ORGANISM: Artificial Sequence
144
     <220> FEATURE:
```

DATE: 02/10/2000 RAW SEQUENCE LISTING PAGE: 4 TIME: 12:11:55

· 1

PATENT APPLICATION US/09/267,511

```
<223> OTHER INFORMATION: Description of Artificial Sequence: 2-R in ADNF I
            polypeptide formula
146
147
      <400> SEQUENCE: 9
            Val Leu Gly Gly
148
149
      <210> SEQ ID NO 10
150
      <211> LENGTH: 5
151
      <212> TYPE: PRT
152
153
      <213> ORGANISM: Artificial Sequence
154
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: 2-R in ADNF I
155
            polypeptide formula
156
      <400> SEQUENCE: 10
157
158
            Val Leu Gly Gly Val
159
160
      <210> SEQ ID NO 11
      <211> LENGTH: 5
161
162
      <212> TYPE: PRT
      <213> ORGANISM: Artificial Sequence
163
      <220> FEATURE:
165
      <223> OTHER INFORMATION: Description of Artificial Sequence: 2-R in ADNF I
            polypeptide formula
166
167
      <400> SEQUENCE: 11
            Gly Val Leu Gly Gly
168
169
              1
                              5
170
      <210> SEQ ID NO 12
171
      <211> LENGTH: 4
172
      <212> TYPE: PRT
173
      <213> ORGANISM: Artificial Sequence
174
      <220> FEATURE:
      <223> OTHER INFORMATION: Description of Artificial Sequence: 4-R in ADNF III
175
176
            polypeptide formula
      <400> SEQUENCE: 12
177
178
            Leu Gly Leu Gly
179
              1
180
      <210> SEQ ID NO 13
181
      <211> LENGTH: 5
182
     <212> TYPE: PRT
183
      <213> ORGANISM: Artificial Sequence
      <220> FEATURE:
184
      <223> OTHER INFORMATION: Description of Artificial Sequence:4-R in ADNF III
185
            polypeptide formula
186
187
      <400> SEQUENCE: 13
188
            Leu Gly Leu Gly Leu
189
     <210> SEQ ID NO 14
190
191
     <211> LENGTH: 19
      <212> TYPE: PRT
192
193
      <213> ORGANISM: Artificial Sequence
      <220> FEATURE:
194
```

RAW SEQUENCE LISTING DATE: 02/10/2000 PAGE: 5 TIME: 12:11:55

PATENT APPLICATION US/09/267,511

Input Set: 1267511.RAW

<223> OTHER INFORMATION: Description of Artificial Sequence: ADNF I 196 polypeptide 197 <400> SEQUENCE: 14 Val Leu Gly Gly Ser Ala Leu Leu Arg Ser Ile Pro Ala Val Leu 198 10 199 200 Gly Gly Gly 201 <210> SEQ ID NO 15 202 <211> LENGTH: 18 203 <212> TYPE: PRT 204 <213> ORGANISM: Artificial Sequence 205 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: ADNF I 206 207 polypeptide 208 <400> SEQUENCE: 15 Val Leu Gly Gly Ser Ala Leu Leu Arg Ser Ile Pro Ala Val Leu 209 210 1 5 Gly Gly 211 212 <210> SEQ ID NO 16 213 <211> LENGTH: 19 214 <212> TYPE: PRT 215 <213> ORGANISM: Artificial Sequence <220> FEATURE: 216 <223> OTHER INFORMATION: Description of Artificial Sequence: ADNF I 217 218 polypeptide 219 <400> SEQUENCE: 16 Val Leu Gly Gly Ser Ala Leu Leu Arg Ser Ile Pro Ala Val Leu 220 221 10 222 Gly Gly Val 223 <210> SEQ ID NO 17 224 <211> LENGTH: 19 225 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence 226 227 <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:ADNF I 228 229 polypeptide 230 <400> SEQUENCE: 17 Val Leu Gly Gly Ser Ala Leu Leu Arg Ser Ile Pro Ala Gly Val 231 232 5 10 233 Leu Gly Gly 234 <210> SEQ ID NO 18 <211> LENGTH: 18 235 <212> TYPE: PRT 237 <213> ORGANISM: Artificial Sequence 238 <220> FEATURE: 239 <223> OTHER INFORMATION: Description of Artificial Sequence: ADNF III polypeptide 240 241 <400> SEQUENCE: 18 Leu Gly Leu Gly Gly Asn Ala Pro Val Ser Ile Pro Gln Leu Gly Leu 242 5 10 15 243 1 244 Gly Gly

PAGE:

VERIFICATION SUMMARY

DATE: 02/10/2000 PATENT APPLICATION US/09/267,511 TIME: 12:11:55

Line	?	Error/Warning							Original Text										
	-																		
58	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Х	
60	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Х	
62	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Ser	Ala	L	
64	W	"N"	or	"Xaa"	used:	Feature	required	Ala	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Х	
66	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Х	
68	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa			
88	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	X	
90	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	X	
92	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Asn	Ala	P	
94	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	X	
96	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	X	
98	W	"N"	or	"Xaa"	used:	Feature	required	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa				